ArticleEuropean journal of medical research2025
Association between advanced lung cancer inflammation index and postoperative mortality in lung cancer patients: a retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CONUT score and Naples prognostic score (NPS) for dual prediction of survival and radiation toxicity in locally advanced non-small cell lung cancer with chemoradiotherapy.Journal of thoracic disease · 2026Article
- The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLung cancer is the leading cause of cancer-related death. Surgical resection of early-stage non-small cell lung cancer (NSCLC) is associated with a suboptimal survival rate and significant adverse outcomes. The advanced lung cancer inflammation index (ALI), which integrates body mass index (BMI), albumin level, and neutrophil-to-lymphocyte ratio (NLR), comprehensively assesses nutritional and inflammatory status, potentially improving prognostic precision in surgical patients.
methodsThis retrospective cohort study analyzed 2447 patients who underwent lung cancer resection (INSPIRE database, South Korea, 2011-2020). The ALI (BMI × Albumin/NLR) was calculated preoperatively. Patients were stratified into high (≥ 37.22) and low (< 37.22) ALI groups (receiver operating characteristic curve-determined cut-off). Associations between ALI and mortality (primary: 90-day; secondary: 180-day, in-hospital) were assessed using multivariate regression after adjusting for demographics, surgical factors, and key laboratory parameters.
resultsThe low ALI group (n = 805) was older (64.2 vs 63.2 years, p = 0.018), had more males (63.2% vs. 51.2%, p < 0.001), and exhibited significantly poorer laboratory profiles (e.g., lower hematocrit and hemoglobin levels; higher white blood cell count and C-reactive protein levels; all p < 0.001) than the high ALI group (n = 1642). Mortality rates were significantly higher in the low ALI group (90-day: 1.6% vs 0.1%; 180-day: 3.2% vs 0.5%; in-hospital: 2.0% vs 0.4%; all p < 0.001). After full adjustment, compared with the low ALI group, the high ALI group had an 82% lower risk of 90-day mortality (HR 0.18, 95% CI 0.04-0.81) and a 70% lower risk of 180-day mortality (HR 0.30, 95% CI 0.13-0.70). Each 1-unit increase in ALI was linked to a 4% reduction in 90-day mortality risk (HR 0.96, 95% CI 0.93-0.99). High ALI was also associated with an 66% lower odds of in-hospital mortality (OR 0.34, 95% CI 0.12-0.96).
conclusionsOur study shows that ALI is significantly associated with poor clinical prognosis after lung cancer resection. The lower the ALI, the higher the 90-day, 180-day, and in-hospital mortality rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.